Thursday, July 7, 2022

Riding the Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) Express

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is another one of the Israeli-based R&D MMJ companies that we have been so bullish on over the recent cycle higher. Development costs are far more efficient, and the regulatory and legal system is more forgiving. Cannabics stock has been on fire of late and we wanted to circle back and take a closer look at what’s behind the move.

As we noted in our prior coverage on CNBX, the company has developed new diagnostic tests based on liquid biopsies of patients suffering from any kind of cancer. The tests use CTC technology that collects cancer cells from patients’ blood samples, and tests their sensitivity to cannabinoid compounds alongside conventional chemotherapy medicine. Company statements indicate that commercialization will commence in March 2017, when 10 first patients’ liquid biopsies will be tested using the company’s new technology. The company plans to make this service available to cancer patients in Canada, Europe and the USA, under local medical cannabis regulations in each country and state, by the end of the year.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) promulgates itself as a company that engages in the research, development, licensing, and marketing of cannabinoid-based treatments and therapies. The company focuses on developing therapies and biotechnological tools for the relief from various ailments that respond to active ingredients sourced from the cannabis plant.

Its flagship product is Cannabics SR, a long-acting medical cannabis capsule that shows therapeutic effects as a palliative care therapy for cancer patients.

The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and academic research as well as current clinical studies underway at Rambam Hospital.

The Company’s scientific focus is on identifying and harnessing the therapeutic properties of specific natural Cannabinoids. Cannabics’ vision is to create individually tailored therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.

The company was formerly known as American Mining Corporation and changed its name to Cannabics Pharmaceuticals Inc. in May 2014. Cannabics Pharmaceuticals Inc. is based in Bethesda, Maryland. As of April 25, 2014, Cannabics Pharmaceuticals Inc. operates as a subsidiary of Cannabics Inc.

According to company materials, “Cannabics Pharmaceuticals Inc. (CNBX), a U.S based public company, is dedicated to the development of Personalized Anti-Cancer and Palliative treatments. The Company’s R&D is based in Israel, where it is licensed by the Ministry of Health for its work in both scientific and clinical research. The Company’s focus is on harnessing the therapeutic properties of natural Cannabinoid formulations and diagnostics. Cannabics’ vision is to create individually tailored natural therapies for cancer patients, utilizing advanced screening systems and personalized bioinformatics tools.”

Find out when Cannabics stock reaches critical levels. Subscribe to Right Now by entering your Email in the box below.

Our sense is this: the huge run in Cannabics stock has intensified in front of the company’s stated target date for commercialization of its new personalized diagnostics technology. This suggests growing excitement in the market where this tech is concerned. It is a novel idea, but the data is not present in any form that can necessarily validate the idea. That said, we will have more and more such data by this time next month, and investors are keen to gain exposure in front of that.

The chart shows just shy of 400% during the past month in terms of shareholder gains in the name. Market participants may want to pay attention to this stock. CNBX has a history of dramatic rallies. Moreover, the stock has witnessed a pop in interest, as transaction volume levels have recently pushed topping 350% beyond its prior sustained average level.

This should not be overlooked given the stock’s relatively small trading float of barely over 14M shares. It’s something the veterans know to key on: ramping trading activity can overwhelm available supply in a stock with this type of small float, leading to an upward burst in prices. Since we last covered the name, the stock has moved 200% higher.

Itamar Borochov, CEO of Cannabics Pharmaceuticals, says “We are the first company in the world to offer cancer patients personalized cannabinoid anti-tumor diagnostics. We are excited to be pioneers in the nexus of cannabis and personalized cancer treatments”.

Earning a current market cap value of $456.5M, CNBX has a store ($278K) of cash on the books, which is balanced by virtually no total current liabilities. CNBX is pulling in trailing 12-month revenues of $113K. However, the company is seeing recent declines on the top line on a sequential quarterly basis, with revenues falling at -100% as of its latest reporting period. We will update the story again soon as developments transpire. For continuing coverage on shares of Cannabics stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!

Related Articles


Please enter your comment!
Please enter your name here

Stay Connected


Latest Articles